An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

NCT00774930 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

115

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoid Syndrome

Interventions

DRUG: Lanreotide
DRUG: Placebo

Sponsor

Ipsen